skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.10e (Release date: 2017-10-30)
SearchBox Top
SearchBox Bottom
Belimumab (Code C91385)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Belimumab

Definition: A fully human IgG1 monoclonal antibody directed against B-Lymphocyte stimulator protein (BlyS or TNFSF13B) with potential immunomodulating activity. Belimumab specifically recognizes and inhibits the biological activity of BlyS, thereby preventing the binding of BlyS to B-lymphocytes. This inhibits the maturation of B-lymphocytes and may induce apoptosis in B-lymphocytes. In addition, it may decrease B-lymphocyte proliferation and/or survival. BlyS, a member of TNF family supporting B-lymphocyte maturation and survival, has been implicated in the pathogenesis of autoimmune diseases and B-lymphocyte malignancies.

Display Name: Belimumab

Label: Belimumab

NCI Thesaurus Code: C91385 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1723401  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Immunoglobulin G1, anti-(Human Cytokine BAFF) (Human Monoclonal LymphoStat-B Heavy Chain), Disulfide with Human Monoclonal LymphoStat-B lambda-chain, Dimer

External Source Codes: 
CAS Registry Number 356547-88-1 (see NLM ChemIDplus info)
FDA UNII Code 73B0K5S26A
PDQ Closed Trial Search ID 680522
PDQ Open Trial Search ID 680522 (check for NCI PDQ open clinical trial info)
UMLS CUI C1723401

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Systemic Lupus Erythematosus
code C91385
Contributing_Source CTRP
Contributing_Source FDA
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom